FLC
REGN icon

Fifth Lane Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Fifth Lane Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,001
Closed – – 174
2023
Q4 		$0 Hold
10,001
– – ﹤0.01% 169
2023
Q3 		$0 Buy
+10,001
New +$7.86M ﹤0.01% 247

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fifth Lane Capital's REGN Position: Q1 2024 in Review

Fifth Lane Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 10,001 shares.

Fifth Lane Capital first reported a position in REGN in Q3 2023 and held it in 2 quarters. The position peaked at $0 in Q4 2023. 1,309 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

  • Fifth Lane Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Fifth Lane Capital sold 10,001 Regeneron Pharmaceuticals shares in Q1 2024.
  • Fifth Lane Capital first reported a position in Regeneron Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Fifth Lane Capital's Regeneron Pharmaceuticals position peaked at $0 in Q4 2023.
  • 1,309 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Fifth Lane Capital's 13F filing for Q1 2024, filed 2 May 2024.